Related Experiment Video
Updated: Apr 17, 2026
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
SOX11-mediated CXCL10/CXCR3 activation promotes neuroendocrine prostate cancer
Hekang Ding1, Qingwei Meng1, Kun He1
1Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Institute of Urology, Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, China.
Abstract:
Neuroendocrine prostate cancer is an aggressive, therapy-resistant subtype of prostate cancer with unclear underlying molecular mechanisms and limited effective treatments. Through single-cell transcriptomic analysis, we found that SOX11 is specifically expressed in neuroendocrine cell populations. Further studies confirmed that SOX11 promotes neuroendocrine transdifferentiation in prostate cancer via CXCL10/CXCR3 activation, thereby enhancing the migration and invasion abilities of prostate cancer cells. These results suggest that SOX11 may play a central role in driving neuroendocrine prostate cancer progression, which is expected to serve as a candidate factor for subsequent therapeutic exploration. SIGNIFICANCE STATEMENT: This study reveals the mechanism by which the SOX11/CXCL10/CXCR3 axis promotes neuroendocrine transdifferentiation of prostate cancer, thereby identifying potential targets for the development of targeted therapeutic strategies against neuroendocrine prostate cancer.
